<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482453</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-788-1001</org_study_id>
    <secondary_id>U1111-1208-9582</secondary_id>
    <nct_id>NCT03482453</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants</brief_title>
  <official_title>Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Open-Label, Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability of TAK-788 and to identify a
      tolerable single oral dose of TAK-788 administered as a drug-in-capsule (DiC) formulation, to
      characterize the effects of a low-fat meal on the PK of the TAK-788 administered as DiC
      formulation and to evaluate the bioavailability of a test (Process B) DiC of TAK-788 relative
      to a reference (Process A) DiC of TAK-788 in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-788. The study will assess the safety and
      tolerability of single oral dose of TAK-788, evaluate the effect of a low-fat meal on PK of
      TAK-788 and will assess the relative bioavailability of two DiCs of TAK-788.

      The study will enroll approximately 69 participants. The study is designed to consist of 3
      parts: Part 1- dose escalation phase, Part 2- low fat meal effect and Part 3 - relative
      bioavailability. The study population of Part 1 will consist of 40 participants enrolled into
      5 cohorts. Each cohort will have 8 randomized participants with 6 receiving a single dose of
      TAK-788, and 2 receiving matching placebo under fasted conditions. In Cohorts 1 to 5, safety
      of single-dose TAK-788 will be evaluated. For Part 2, the effect of a low-fat meal on a
      single tolerable dose of TAK-788 will be determined following review of safety and
      tolerability data from the previous cohorts in Part 1. The study population of Part 2 will
      consist of 16 participants enrolled into 2 cohorts of different doses, where participants
      will be randomized to a cross-over sequence of:

        -  TAK-788 Fed + TAK-788 Fasted

        -  TAK-788 Fasted + TAK-788 Fed

      The study population of Part 3 will consist of 13 participants enrolled into 1 cohort, where
      participants will be randomized to a cross-over sequence of:

        -  TAK-788 DiC (reference) + TAK-788 DiC (test)

        -  TAK-788 DiC (test) + TAK-788 DiC (reference) This single-center trial will be conducted
           in the United States. The overall time to participate in this study is approximately 7
           months. Participants will be contacted by telephone 30 days after the last dose of study
           drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Actual">January 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Clinically Significant Abnormal Laboratory Values</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Clinically Significant Abnormal Vital Signs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3, Cmax: Maximum Observed Plasma Concentration for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-788 and Its Active Metabolites AP32960 and AP32914</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788 and Its Active Metabolites AP32960 and AP32914</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788 and Its Active Metabolites, AP32960 and AP32914</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788 and Its Active Metabolites AP32960 and AP32914</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788 and Its Active Metabolites AP32960 and AP32914</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2 and 3: Number of Participants Reporting One or More TEAEs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2 and 3: Number of Participants With One or More SAEs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Laboratory Values</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Vital Signs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1: TAK-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2: TAK-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3: TAK-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 4: TAK-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 5: TAK-788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TAK-788 Fed + TAK-788 Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TAK-788 Fasted + TAK-788 Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-788</intervention_name>
    <description>TAK-788 capsules.</description>
    <arm_group_label>Part 1 Cohort 1: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 2: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 3: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 4: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 5: TAK-788</arm_group_label>
    <arm_group_label>Part 2: TAK-788 Fasted + TAK-788 Fed</arm_group_label>
    <arm_group_label>Part 2: TAK-788 Fed + TAK-788 Fasted</arm_group_label>
    <other_name>AP32788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-788 placebo-matching capsules.</description>
    <arm_group_label>Part 1 Cohort 1: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 2: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 3: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 4: TAK-788</arm_group_label>
    <arm_group_label>Part 1 Cohort 5: TAK-788</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-788</intervention_name>
    <description>TAK-788 DiC.</description>
    <arm_group_label>Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)</arm_group_label>
    <arm_group_label>Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)</arm_group_label>
    <other_name>AP32788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body weight of greater than or equal to (&gt;=) 45 kilogram (kg) (women) or &gt;=55 kg (men)
             and a body mass index of 18.0 to 30.0 kilogram per square meter (kg/m^2) at screening.

          2. Nonsmoker (never smoked or greater than [&gt;] 20 years from last occurrence of smoking).

          3. Normal organ function including hepatic, renal, and bone marrow function.

        Exclusion Criteria:

          1. Manifestations of malabsorption due to prior gastro-intestinal (GI) surgery, GI
             disease, or for an unknown other reason that may alter the PK of TAK-788.

          2. Pulmonary infection ongoing or within 30 days of informed consent.

          3. Inability to undergo venipuncture and/or tolerate venous access.

          4. Inability to tolerate multiple blood sampling.

          5. Ongoing or active infection, including but not limited to, the requirement for
             intravenous (IV) antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <results_first_submitted>January 16, 2020</results_first_submitted>
  <results_first_submitted_qc>January 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03482453/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03482453/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 28 March 2018 to 18 January 2019.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in this 3 parts study to receive: TAK-788 as a single rising dose of 20 milligram (mg), 40 mg, 80 mg, 120 mg, 160 mg in Part 1; TAK-788 in a 2-way cross-over design with or without a low-fat meal in Part B; or in a 2-way cross-over sequence to receive TAK-788 drug in capsule (DiC) A or B in Part 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Pooled Placebo</title>
          <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Cohort 1: TAK-788 20 mg</title>
          <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Cohort 2: TAK-788 40 mg</title>
          <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 Cohort 3: TAK-788 80 mg</title>
          <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 Cohort 4: TAK-788 120 mg</title>
          <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 Cohort 5: TAK-788 160 mg</title>
          <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: TAK-788 120 mg Fed + TAK-788 120 mg Fasted</title>
          <description>TAK-788 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B).</description>
        </group>
        <group group_id="P8">
          <title>Part 2: TAK-788 120 mg Fasted + TAK-788 120 mg Fed</title>
          <description>TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A).</description>
        </group>
        <group group_id="P9">
          <title>Part 2: TAK-788 160 mg Fed + TAK-788 160 mg Fasted</title>
          <description>TAK-788 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B).</description>
        </group>
        <group group_id="P10">
          <title>Part 2: TAK-788 160 mg Fasted + TAK-788 160 mg Fed</title>
          <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A).</description>
        </group>
        <group group_id="P11">
          <title>Part 3: TAK-788 DiC A + TAK-788 DiC B</title>
          <description>TAK-7 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
        </group>
        <group group_id="P12">
          <title>Part 3: TAK-788 DiC B + TAK-788 DiC A</title>
          <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Parts 2, 3 Intervention Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Parts 2, 3 Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Parts 2, 3 Intervention Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all participants who received any study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Pooled Placebo</title>
          <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Cohort 1: TAK-788 20 mg</title>
          <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Cohort 2: TAK-788 40 mg</title>
          <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 Cohort 3: TAK-788 80 mg</title>
          <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 Cohort 4: TAK-788 120 mg</title>
          <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 Cohort 5: TAK-788 160 mg</title>
          <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: TAK-788 120 mg Fed + TAK-788 120 mg Fasted</title>
          <description>TAK-788 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B).</description>
        </group>
        <group group_id="B8">
          <title>Part 2: TAK-788 120 mg Fasted + TAK-788 120 mg Fed</title>
          <description>TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A).</description>
        </group>
        <group group_id="B9">
          <title>Part 2: TAK-788 160 mg Fed + TAK-788 160 mg Fasted</title>
          <description>TAK-788 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B).</description>
        </group>
        <group group_id="B10">
          <title>Part 2: TAK-788 160 mg Fasted + TAK-788 160 mg Fed</title>
          <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A).</description>
        </group>
        <group group_id="B11">
          <title>Part 3: TAK-788 DiC A + TAK-788 DiC B</title>
          <description>TAK-7 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
        </group>
        <group group_id="B12">
          <title>Part 3: TAK-788 DiC B + TAK-788 DiC A</title>
          <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Pooled Placebo</title>
            <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With One or More Serious Adverse Events (SAEs)</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Pooled Placebo</title>
            <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With One or More Serious Adverse Events (SAEs)</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Pooled Placebo</title>
            <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Clinically Significant Abnormal Vital Signs</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 31)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Pooled Placebo</title>
            <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Clinically Significant Abnormal Vital Signs</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Cmax: Maximum Observed Plasma Concentration for TAK-788</title>
          <population>The pharmacokinetic (PK) set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.52" spread="11.423"/>
                    <measurement group_id="O2" value="31.24" spread="16.682"/>
                    <measurement group_id="O3" value="39.51" spread="17.179"/>
                    <measurement group_id="O4" value="41.00" spread="21.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The least square means (LS means) for the log-transformed parameters were exponentiated to obtain the point estimates and 90 percent (%) Confidence Intervals (CIs) of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.8810</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7108</ci_lower_limit>
            <ci_upper_limit>1.0921</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The LS means for the log-transformed parameters were exponentiated to obtain the point estimates and 90% CIs of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.9637</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8361</ci_lower_limit>
            <ci_upper_limit>1.1107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3, Cmax: Maximum Observed Plasma Concentration for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: TAK-788 DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: TAK-788 DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3, Cmax: Maximum Observed Plasma Concentration for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.77" spread="14.738"/>
                    <measurement group_id="O2" value="41.71" spread="11.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The LS means for the log-transformed parameters were exponentiated to obtain the point estimates and 90% CIs of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.9317</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8458</ci_lower_limit>
            <ci_upper_limit>1.0263</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="6.0" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O4" value="6.0" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: TAK-788 DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: TAK-788 DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526.3" spread="272.72"/>
                    <measurement group_id="O2" value="518.3" spread="300.84"/>
                    <measurement group_id="O3" value="700.6" spread="295.10"/>
                    <measurement group_id="O4" value="733.6" spread="461.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: TAK-788 DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: TAK-788 DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706.1" spread="173.63"/>
                    <measurement group_id="O2" value="677.9" spread="239.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533.8" spread="272.07"/>
                    <measurement group_id="O2" value="525.8" spread="301.84"/>
                    <measurement group_id="O3" value="706.3" spread="294.61"/>
                    <measurement group_id="O4" value="743.0" spread="462.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The LS means for the log-transformed parameters were exponentiated to obtain the point estimates and 90% CIs of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>1.0153</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8977</ci_lower_limit>
            <ci_upper_limit>1.1483</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The LS means for the log-transformed parameters were exponentiated to obtain the point estimates and 90% CIs of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.9506</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8740</ci_lower_limit>
            <ci_upper_limit>1.0339</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: TAK-788 DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: TAK-788 DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738.8" spread="193.06"/>
                    <measurement group_id="O2" value="709.5" spread="262.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>A linear mixed effect model on the natural log-transformed parameters was performed with regimen, sequence and period as a fixed effect and subject nested within sequence as a random effect. The LS means for the log-transformed parameters were exponentiated to obtain the point estimates and 90% CIs of the geometric LS mean ratio on the original scale.</non_inferiority_desc>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.9603</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8861</ci_lower_limit>
            <ci_upper_limit>1.0408</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.17" spread="2.629"/>
                    <measurement group_id="O2" value="17.60" spread="4.067"/>
                    <measurement group_id="O3" value="20.72" spread="4.827"/>
                    <measurement group_id="O4" value="20.62" spread="6.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: TAK-788 DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: TAK-788 DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.38" spread="2.007"/>
                    <measurement group_id="O2" value="16.38" spread="2.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.938"/>
                    <measurement group_id="O2" value="7.85" spread="4.206"/>
                    <measurement group_id="O3" value="14.66" spread="11.649"/>
                    <measurement group_id="O4" value="25.81" spread="9.682"/>
                    <measurement group_id="O5" value="52.21" spread="27.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32960</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" spread="0.4914"/>
                    <measurement group_id="O2" value="3.483" spread="0.8827"/>
                    <measurement group_id="O3" value="8.298" spread="5.5055"/>
                    <measurement group_id="O4" value="13.417" spread="5.5667"/>
                    <measurement group_id="O5" value="25.411" spread="10.7473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32914</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data could not be derived since concentration values were below quantifiable limit less than (&lt;) 0.1 ng/mL.</measurement>
                    <measurement group_id="O2" value="0.735" spread="0.2221"/>
                    <measurement group_id="O3" value="1.315" spread="1.0492"/>
                    <measurement group_id="O4" value="2.036" spread="0.6433"/>
                    <measurement group_id="O5" value="4.051" spread="1.8778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2" upper_limit="8.08"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="4.0" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O4" value="6.0" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O5" value="6.0" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32960</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2" upper_limit="8.08"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O4" value="6.0" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="O5" value="5.0" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32914</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data could not be derived since concentration values were below quantifiable limit &lt; 0.1 ng/mL.</measurement>
                    <measurement group_id="O2" value="6.0" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O3" value="4.0" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O4" value="6.0" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="O5" value="6.0" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788 and Its Active Metabolites, AP32960 and AP32914</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for TAK-788 and Its Active Metabolites, AP32960 and AP32914</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-788</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="7.07"/>
                    <measurement group_id="O2" value="155.2" spread="112.06"/>
                    <measurement group_id="O3" value="250.4" spread="197.25"/>
                    <measurement group_id="O4" value="448.3" spread="184.43"/>
                    <measurement group_id="O5" value="1007.8" spread="596.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32960</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="6.41"/>
                    <measurement group_id="O2" value="74.9" spread="21.89"/>
                    <measurement group_id="O3" value="159.3" spread="77.04"/>
                    <measurement group_id="O4" value="284.0" spread="125.52"/>
                    <measurement group_id="O5" value="538.5" spread="196.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32914</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data could not be derived since concentration values were below quantifiable limit less than 0.1 ng/mL.</measurement>
                    <measurement group_id="O2" value="11.53" spread="6.092"/>
                    <measurement group_id="O3" value="14.59" spread="11.845"/>
                    <measurement group_id="O4" value="31.74" spread="11.370"/>
                    <measurement group_id="O5" value="80.40" spread="47.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters. The PK analysis population where data at specified time points were available.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-788</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="7.11"/>
                    <measurement group_id="O2" value="160.4" spread="115.57"/>
                    <measurement group_id="O3" value="256.9" spread="203.43"/>
                    <measurement group_id="O4" value="456.1" spread="187.20"/>
                    <measurement group_id="O5" value="1017.3" spread="599.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32960</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="6.23"/>
                    <measurement group_id="O2" value="79.8" spread="22.41"/>
                    <measurement group_id="O3" value="165.9" spread="81.28"/>
                    <measurement group_id="O4" value="293.4" spread="124.35"/>
                    <measurement group_id="O5" value="548.0" spread="198.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32914</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data could not be derived since concentration values were below quantifiable limit less than 0.1 ng/mL.</measurement>
                    <measurement group_id="O2" value="19.27" spread="3.111"/>
                    <measurement group_id="O3" value="20.34" spread="12.714"/>
                    <measurement group_id="O4" value="34.58" spread="11.482"/>
                    <measurement group_id="O5" value="85.16" spread="48.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose</time_frame>
        <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters. The PK analysis population where data at specified time points were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1: TAK-788 20 mg</title>
            <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2: TAK-788 40 mg</title>
            <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3: TAK-788 80 mg</title>
            <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 Cohort 4: TAK-788 120 mg</title>
            <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 Cohort 5: TAK-788 160 mg</title>
            <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, t1/2z: Terminal Disposition Phase Half-life (t1/2z) for TAK-788 and Its Active Metabolites AP32960 and AP32914</title>
          <population>The PK set included all participants in the safety set who had no major protocol deviations that would have affected the PK analysis and who had sufficient data to calculate PK parameters. The PK analysis population where data at specified time points were available.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-788</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.07" spread="1.477"/>
                    <measurement group_id="O2" value="15.95" spread="4.593"/>
                    <measurement group_id="O3" value="14.25" spread="4.310"/>
                    <measurement group_id="O4" value="18.30" spread="1.286"/>
                    <measurement group_id="O5" value="19.85" spread="5.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32960</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.96" spread="3.461"/>
                    <measurement group_id="O2" value="21.43" spread="2.979"/>
                    <measurement group_id="O3" value="22.19" spread="1.137"/>
                    <measurement group_id="O4" value="28.93" spread="5.903"/>
                    <measurement group_id="O5" value="29.18" spread="6.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite AP32914</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Data could not be derived since concentration values were below quantifiable limit less than 0.1 ng/mL.</measurement>
                    <measurement group_id="O2" value="13.75" spread="3.323"/>
                    <measurement group_id="O3" value="12.22" spread="2.084"/>
                    <measurement group_id="O4" value="12.02" spread="1.162"/>
                    <measurement group_id="O5" value="16.09" spread="4.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 2 and 3: Number of Participants Reporting One or More TEAEs</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-788 160 mg DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 3: TAK-788 160 mg DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 2 and 3: Number of Participants Reporting One or More TEAEs</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 2 and 3: Number of Participants With One or More SAEs</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-788 160 mg DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 3: TAK-788 160 mg DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 2 and 3: Number of Participants With One or More SAEs</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg</title>
            <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A).</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-788 160 mg DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 3: TAK-788 160 mg DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Laboratory Values</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Vital Signs</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Day 38) (end of Intervention Period 2)</time_frame>
        <population>The safety set included all participants who received any study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-788 120 mg Fed</title>
            <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-788 120 mg Fasted</title>
            <description>TAK-788, 120 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-788 160 mg Fed</title>
            <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-788 160 mg Fasted</title>
            <description>TAK-788, 160 mg, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B).</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-788 160 mg DiC A</title>
            <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 3: TAK-788 160 mg DiC B</title>
            <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 2 and 3: Number of Participants With Clinically Significant Abnormal Vital Signs</title>
          <population>The safety set included all participants who received any study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs are adverse events that started after the first dose of study drug and no more than 30 days (up to Day 31 in Part 1; Day 38 in Parts 2 and 3 [end of intervention period 2]) after the last dose of study drug</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Pooled Placebo</title>
          <description>TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Cohort 1: TAK-788 20 mg</title>
          <description>TAK-788 20 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Cohort 2: TAK-788 40 mg</title>
          <description>TAK-788 40 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 Cohort 3: TAK-788 80 mg</title>
          <description>TAK-788 80 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1 Cohort 4: TAK-788 120 mg</title>
          <description>TAK-788 120 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 Cohort 5: TAK-788 160 mg</title>
          <description>TAK-788 160 mg, capsule, orally, once under fasted conditions on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: TAK-788 120 mg Fed</title>
          <description>TAK-788 120 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
        <group group_id="E8">
          <title>Part 2: TAK-788 120 mg Fasted</title>
          <description>TAK-788, 120 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: TAK-788 160 mg Fed</title>
          <description>TAK-788, 160 mg, capsule, orally, under fed conditions with low-fat meal (Treatment A), once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: TAK-788 160 mg Fasted</title>
          <description>TAK-788, 160 mg, capsule, orally, under fasted conditions (Treatment B), once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
        <group group_id="E11">
          <title>Part 3: TAK-788 DiC A</title>
          <description>TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
        <group group_id="E12">
          <title>Part 3: TAK-788 DiC B</title>
          <description>TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of either Intervention Period 1 or 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

